Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection

International Journal of Medical Microbiology

Volumn 304, Issue 8, 2014, Pages 1182-1191

  Martina, Pablo ^a   Feliziani, Sofía ^b   Juan, Carlos ^c   Bettiol, Marisa ^d   Gatti, Blanca ^d   Yantorno, Osvaldo ^a   Smania, Andrea M ^b   Oliver, Antonio ^c   Bosch, Alejandra ^a  

^a Universidad Nacional de La Plata   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d Hospital de Ninos Sor Maria Ludovica   (Argentina)

Author keywords

Antibiotic resistance; Burkholderia cepacia complex; Chronic infection; Cystic fibrosis; Hypermutation; Mismatch repair system

Indexed keywords

CIPROFLOXACIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA CONTAMINAN; BURKHOLDERIA LATA; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA SEMINALIS; BURKHOLDERIA VIETNAMIENSIS; CLINICAL ARTICLE; CYSTIC FIBROSIS; GENE SEQUENCE; HUMAN; HYPERMUTATION; LUNG INFECTION; MISMATCH REPAIR; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; RESPIRATORY TRACT INFECTION; SPONTANEOUS MUTATION;

EID: 84940165948     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.08.011     Document Type: Article

References (48)

1. Baldwin A., Mahenthiralingam E., Drevinek P., Vandamme P., Govan J.R., Waine D.J., Lipuma J.J., Chiarini L., Dalmastri C., Henry D.A., Speert D.P., Honeybourne D., Maiden M.C.J., Dowson C.G. Environmental Burkholderia cepacia complex isolates in human infections. Emerg. Infect. Dis. 2007, 13:458-461.
2. Blázquez J., Couce A., Rodríguez-Beltrán J., Rodríguez-Rojas A. Antimicrobials as promoters of genetic variation. Curr. Opin. Microbiol. 2012, 15:561-569.
3. Bosch A., Miñán A., Vescina C., Degrossi J., Gatti B., Montanaro P., Messina M., Franco M., Vay C., Schmitt J., Naumann D., Yantorno O. Fourier transform infrared spectroscopy for rapid identification of nonfermenting gram-negative bacteria isolated from sputum samples from cystic fibrosis patients. J. Clin. Microbiol. 2008, 46:2535-2546.
4. Ciofu O., Riis B., Pressler T., Enghusen H., Høiby N., Poulsen H.E. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 2005, 49:2276-2282.
5. CLSI, 2011. Performance standards for antimicrobial susceptibility testing; Seventeenth Informational Supplement M100-S21, Clinical. ed. Pennsylvania, USA.
6. Coenye T., Vandamme P. Diversity and significance of Burkholderia species occupying diverse ecological niches. Environ. Microbiol. 2003, 5:719-729.
7. Correia S., Nascimento C., Pereira L., Cunha M., Sá-Correia I., Barreto C. The clinical course of Burkholderia cepacia complex bacteria respiratory infection in cystic fibrosis patients. Rev. Port. Pneumol. 2008, 14:5-26.
8. Cramer N., Klockgether J., Wrasman K., Schmidt M., Davenport C.F., Tümmle B. Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs. Environ. Microbiol. 2011, 13:1690-1704.
9. Del Campo R., Go E., Pedrosa D., Mun C., Ma L., Baquero F., Canto R. Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J. Clin. Microbiol. 2005, 43:2207-2214.
10. Drevinek P., Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin. Microbiol. Infect. 2010, 16:821-830.
11. Feliziani S., Luján A.M., Moyano A.J., Sola C., Bocco J.L., Montanaro P., Canigia L.F., Argaraña C.E., Smania A.M. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections. PLoS ONE 2010, 5:1-12.
12. Ferroni A., Guillemot D., Moumile K., Bernede C., Le Bourgeois M. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr. Pulmonol. 2009, 44:820-825.
13. Gould C.V., Sniegowski P.D., Shchepetov M., Metlay J.P., Weiser J.N. Identifying mutator phenotypes among fluoroquinolone-resistant strains of Streptococcus pneumoniae using fluctuation analysis. Antimicrob. Agents Chemother. 2007, 51:3225-3229.
14. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology 2007, 153:917-923.
15. Hoboth C., Hoffmann R., Eichner A., Henke C., Schmoldt S., Imhof A., Heesemann J., Hogardt M. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 2009, 200:118-130.
16. Hoffman L.R., Kulasekara H.D., Emerson J., Houston L.S., Burns J.L., Ramsey B.W., Miller S.I. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J. Cyst. Fibros. 2009, 8:66-70.
17. Jordá-Vargas L., Degrossi J., Castañeda N.C., D'Aquino M., Valvano M.a., Procopio A., Galanternik L., Centrón D. Prevalence of indeterminate genetic species of Burkholderia cepacia complex in a cystic fibrosis center in Argentina. J. Clin. Microbiol. 2008, 46:1151-1152.
18. Kenna D.T., Doherty C.J., Foweraker J., Macaskill L., Barcus V.a., Govan J.R.W. Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 2007, 153:1852-1859.
19. LeClerc J., Li B., Payne W., Cebula T. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996, 274(80):1208-1211.
20. Leitão J.H., Sousa S.a., Cunha M.V., Salgado M.J., Melo-Cristino J., Barreto M.C., Sá-Correia I. Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur. J. Clin. Microbiol. Infect. Dis. 2008, 27:1101-1111.
21. Lieberman T.D., Flett K.B., Yelin I., Martin T.R., McAdam A.J., Priebe G.P., Kishony R. Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat. Genet. 2014, 46:82-87.
22. Lipuma J.J. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 2010, 23:299-323.
23. Macia M.D., Blanquer D., Togores B., Sauleda J., Perez J.L., Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 2005, 49:3382-3386.
24. Mahenthiralingam E., Baldwin A., Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J. Med. Microbiol. 2002, 51:533-538.
25. Mahenthiralingam E., Urban T.a., Goldberg J.B. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol. 2005, 3:144-156.
26. Mahenthiralingam E., Baldwin a, Dowson C.G. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J. Appl. Microbiol. 2008, 104:1539-1551.
27. Martina P., Bettiol M., Vescina C., Montanaro P., Mannino M.C., Prieto C.I., Vay C., Naumann D., Schmitt J., Yantorno O., Lagares A., Bosch A. Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J. Clin. Microbiol. 2013, 51:339-344.
28. Marvig R.L., Johansen H.K., Molin S., Jelsbak L. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet. 2013, 9:e1003741.
29. Mena A., Smith E.E., Burns J.L., Speert D.P., Moskowitz S.M., Perez J.L., Oliver A. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J. Bacteriol. 2008, 190:7910-7917.
30. Miñán A., Bosch A., Lasch P., Stämmler M., Serra D.O., Degrossi J., Gatti B., Vay C., D'aquino M., Yantorno O., Naumann D. Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry. Analyst 2009, 134:1138-1148.
31. Mira N.P., Madeira A., Moreira A.S., Coutinho C.P., Sá-Correia I. Genomic expression analysis reveals strategies of Burkholderia cenocepacia to adapt to cystic fibrosis patients' airways and antimicrobial therapy. PLoS ONE 2011, 6:e28831.
32. Mowat E., Paterson S., Fothergill J.L., Wright E.A., Ledson M.J., Walshaw M.J., Brockhurst M.A., Winstanley C. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 2011, 183:1674-1679.
33. Ng P., Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003, 31:3812-3814.
34. Nørskov-lauritsen N., Johansen H.K., Mette G., Nielsen X.C., Pressler T., Hanne V., Høiby N., Fenger M.G., Olesen H.V. Unusual distribution of Burkholderia cepacia complex species in danish cystic fibrosis clinics may stem from restricted transmission between patients. J. Clin. Microbiol. 2010, 48:1-4.
35. Oliver a., Mena a. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin. Microbiol. Infect. 2010, 16:798-808.
36. Oliver A., Canton R., Campo P., Baquero F., Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288(80):1251-1253.
37. Oliver A., Baquero F., Blázquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol. Microbiol. 2002, 43:1641-1650.
38. Peeters C., Zlosnik J.E.a., Spilker T., Hird T.J., LiPuma J.J., Vandamme P. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. Syst. Appl. Microbiol. 2013, 36:483-489.
39. Pope C.F., Gillespie S.H., Moore J.E., McHugh T.D. Approaches to measure the fitness of Burkholderia cepacia complex isolates. J. Med. Microbiol. 2010, 59:679-686.
40. Prunier A., Malbruny B., Laurans M., Brouard J., Duhamel J., Leclercq R. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 2003, 187:1709-1716.
41. Román F., Cantón R., Pérez-Vázquez M., Baquero F., Campos J. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J. Clin. Microbiol. 2004, 42:1450-1459.
42. Sniegowski P., Gerrish P., Johnson T., Shaver A. The evolution of mutation rates: separating causes from consequences. Bioessays 2000, 22:1057-1066.
43. Strateva T., Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J. Med. Microbiol. 2009, 58:1133-1148.
44. Turrientes M.C., Baquero M.R., Sánchez M.B., Valdezate S., Escudero E., Berg G., Cantón R., Baquero F., Galán J.C., Martínez J.L. Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl. Environ. Microbiol. 2010, 76:1746-1758.
45. Vanlaere E., Lipuma J.J., Baldwin A., Henry D., De Brandt E., Mahenthiralingam E., Speert D., Dowson C., Vandamme P. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int. J. Syst. Evol. Microbiol. 2008, 58:1580-1590.
46. Vanlaere E., Baldwin A., Gevers D., Henry D., De Brandt E., LiPuma J.J., Mahenthiralingam E., Speert D.P., Dowson C., Vandamme P. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int. J. Syst. Evol. Microbiol. 2009, 59:102-111.
47. Workentine M.L., Sibley C.D., Glezerson B., Purighalla S., Norgaard-Gron J.C., Parkins M.D., Rabin H.R., Surette M.G. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 2013, 8:e60225.
48. Zhou J., Chen Y., Tabibi S., Alba L., Garber E., Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 2007, 51:1085-1088.